StockData

BGM Group Ltd. (BGM) stock analysis

BGMNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Jul 21, 2026Score 9/30
$7.70−0.31 (-3.87%)

Close on Nov 12, 2026Market cap $3.09BP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth2Performance2Health5Dividend0

Mixed9 of 30 checks passed

BGM passes 9 of the 30 checks behind our score; 16 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
2/6
Past performance
2/6
Financial health
5/6
Dividend
0/6

What stands out

  • No debt

    BGM has no borrowings on its latest balance sheet.

  • Interest well covered

    No meaningful interest expense to cover.

  • Debt covered by cash flow

    There is no debt to cover.

  • Growing faster than the industry

    Revenue grew 51.1% over the last twelve months; the Drugs median is 8.0%.

What to watch

  • Return on equity under 15%

    Return on equity was -9.2% over the last twelve months and averaged -3.8% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -4.8%, below the 10% that usually covers the cost of capital.

  • Revenue growing under 10% a year

    Revenue grew -16.4% a year over the last three fiscal years, short of the 10% we look for.

  • Net margin below its 5-year average

    Net margin was -52.6% over the last twelve months, against a 5-year average of -13.6%.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth2/6

  • Revenue growing under 10% a year

    Revenue grew -16.4% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 51.1% over the last twelve months; the Drugs median is 8.0%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin improving

    Gross margin was 16.6% over the last twelve months, against 16.4% a year earlier.

Past performance2/6

  • Return on equity under 15%

    Return on equity was -9.2% over the last twelve months and averaged -3.8% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -4.8%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    BGM's return on equity of -9.2% is above the Drugs median of -58.9%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin below its 5-year average

    Net margin was -52.6% over the last twelve months, against a 5-year average of -13.6%.

  • Net margin above the industry

    BGM's net margin of -52.6% is above the Drugs median of -53.0%.

Financial health5/6

  • No debt

    BGM has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest well covered

    No meaningful interest expense to cover.

  • Short-term assets cover short-term debts

    Current assets are 1.24 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6

  • No dividend

    BGM has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for BGM. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day
$82.36K
Value traded per 1% price move
$4.15K

Downside

High risk

Typical loss in a bad month
72.3%
Volatility (annualized)
123%
Sharpe ratio, 1 year
-0.82
Beta to the S&P 500 (5Y)
0.27

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2017 to 2025

Gross margin

16.6%+1.6 pts over 5 years

Operating margin

-33.2%−42.8 pts over 5 years

Net margin

-52.6%−62.7 pts over 5 years

See a number that looks wrong?